Comparison of the prognostic value of different inflammation-based scores in patients with hepatocellular carcinoma after Lenvatinib therapy

Table 2 Systemic inflammation-based prognostic scores

Variable	Score
C-reactive protein, mg/L
≤ 7.9	0
> 7.9	1
Platelet-to-lymphocyte ratio
Platelet count (× 109/L): Lymphocyte count (× 109/L) ≤ 269.51	0
Platelet count (× 109/L): Lymphocyte count (× 109/L) > 269.51	1
Neutrophil-to-lymphocyte ratio
Neutrophil count (× 109/L): Lymphocyte count (× 109/L) ≤ 3.28	0
Neutrophil count (× 109/L): Lymphocyte count (× 109/L) > 3.28	1
Lymphocyte-to-C-reactive protein ratio
104 × lymphocyte count (× 109/L): CRP (mg/L) > 2500	0
104 × lymphocyte count (× 109/L): CRP (mg/L) ≤ 2500	1
Lymphocyte-to-monocyte ratio
Lymphocyte count (× 109/L): Monocyte count (× 109/L) ≤ 2.41	0
Lymphocyte count (× 109/L): Monocyte count (× 109/L) > 2.41	1
Systemic immune-inflammation index
Platelet count (× 109/L) × neutrophil count (× 109/L)/Lymphocyte count (× 109/L) ≤ 768.03	0
Platelet count (× 109/L) × neutrophil count (× 109/L)/Lymphocyte count (× 109/L) > 768.03	1
C-reactive protein-to-albumin ratio
C-reactive protein (mg/L): Albumin (g/L) ≤ 0.19	0
C-reactive protein (mg/L): Albumin (g/L) > 0.19	1
Prognostic nutritional index
Albumin (g/L) + 5 × lymphocyte count (× 109/L) > 49.1	0
Albumin (g/L) + 5 × lymphocyte count (× 109/L) ≤ 49.1	1

CRP: C-reactive protein.